Clinical trial · Interventional
HA-WBRT vs SRS in Patients With Multiple Brain Metastases
Hippocampal Avoidance Whole Brain Radiotherapy (HA-WBRT) and Stereotactic Radiosurgery (SRS) in Patients With Multiple Brain Metastases
NCT04277403CI-TRIAL-00053692HipSterunknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study compares the effectiveness and safety of two radiation treatment techniques for patients with multiple brain metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost | Radiation | — | UNRESOLVED |
| Single session or hypofractionated stereotactic radiosurgery | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- HA-WBRT+SIB
- description
- Hippocampal avoiding Whole brain radiation therapy (HA-WBRT) with volumetric modulated arc therapy (VMAT) with a simultaneously integrated boost (SIB) to each brain metastasis
- interventionNames
- Radiation: Hippocampal Avoiding Whole Brain Radiation Therapy with Simultaneous Integrated Boost
- type
- ACTIVE_COMPARATOR
- label
- SRS
- description
- Single session or hypofractionated stereotactic radiosurgery (SRS) of multiple brain metastases
- interventionNames
- Radiation: Single session or hypofractionated stereotactic radiosurgery
Primary outcomes (1)
- measure
- Intracranial Progression free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * At least 4 and not exceeding 15 brain metastases not exceeding a combined total volume of 25ml and not previously treated with radiotherapy * KPI ≥ 70, ECOG ≤ 2 * Age ≥ 18 years, Male or female Exclusion Criteria: * Neuroendocrine, SCLC, germinoma or lymphoma histology * Brain stem metastasis * Life expectancy \< 3 months * Suspicion of meningeosis carcinomatosa * Previous WBRT * Inability to participate in radiologic follow-up, contraindication to MR imaging (e.g. not MRI compatible pacemaker, severe claustrophobia) * Inability to participate in neurocognitive function testing, insufficient German language skills, aphasia, graphomotor impairment, insufficient vision, insufficient attention span * Pregnancy, nursing or unwillingness to prevent pregnancy using effective methods of contraception during treatment * Known abuse of medication, drugs or alcohol * Known severe dementia (z-score \< 2) or major cognitive function disorder that is not caused by intracranial tumour * Known clinical depression or psychotic disorder
References
Publications (0)
Data not yet available
No reference posted for this study.